Trial Profile

Post Marketing Surveillance On The Safety And Tolerability Of Sunitinib Malate (Sutent) For Filipino Patients.

Status: Discontinued

Phase of Trial: Phase IV

Latest Information Update: 08 Jul 2013

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sunitinib (Primary)
Indications Gastrointestinal stromal tumours; Renal cell carcinoma
Focus Adverse reactions
Sponsors Pfizer

Most Recent Events

03 Jul 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
05 Feb 2013 Planned end date changed from 1 Sep 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.
17 Jan 2012 Planned end date changed from 1 Sep 2012 to 1 Sep 2013 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com